Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML Patients
Study sponsor: BioLineRx, Ltd. · BLRX
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2016-03Actual
Enrollment · participants42Actual
Source updated2024-09-19Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.